Chinese pharmaceutical firm Zion Pharma has secured nearly $20 million in a Series A+ round of financing, while early-stage investment company Langsin Venture has closed a new RMB-denominated fund at 120 million yuan ($17 million).
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
